Jinan Jiage biological technology co., LTD(expird)
Free supplier
- Free
supplier - 8th
years
Free supplier
Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
CAS NO.21462-39-5
Enterprise standard(1-10)GramEnterprise standard(11-100)Gram
1)Standard: Enterprise Standard
2)All Purity≥99%
3)We are manufacturer and can provide high quality products with factory price.
1)Parcel can be sent out in 24 hours after payment. Tracking number available
2)Secure and discreet shipment. Various transportation methods for your choice.
3)Customs pass rate ≥99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.
1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.
| Synonyms |
CLEOCIN;CLEOCIN HYDROCHLORIDE;CLINDAMYCIN HCL |
| CAS NO |
21462-39-5 |
| MF |
C18H34Cl2N2O5S |
| MW |
461.44 |
| Purity |
99% |
| Appearance |
White Solid |
| Certification |
GMP，ISO 9001，BP |
| Standard |
Enterprise standard |
| Usage |
antibacterial,inhibits protein synthesis |
| Packing |
Discreet packing ways as your requirement, 100% go through |
| Storage |
Store in cool and dry area and keep away from direct sunlight.
|
Mainly used for infection of abdominal cavity and gynecology caused by anaerobic bacteria.
Also used for respiratory tract, joints and soft tissue, bone tissue, biliary infection caused by sensitive
gram-positive bacterium. Of cause of, etc. And also for Sepsis, endocarditis, etc.
C- This product is the preferred therapy drug for staphylococcus aureus osteomyelitis.
A- For respiratory tract infection, osteomyelitis, joints and soft tissue infection, biliary tract infection
caused by staphylococcus aureus, streptococcus pneumoniae, streptococcus pneumoniae.
B- Also can be used for some anaerobic bacteria infection
C- External use for the treatment of gram-positive bacteria suppurative infection.
1)antibacterial, inhibits protein synthesis
2)Semi-synthetic antibiotic prepared from Lincomycin
3)Clindamycin hydrochloride is a salt of clindamycin, a semi-synthetic lincosamide. The hydrochloride
salt forms at the basic N-ethylproline moiety and is the preferred pharmaceutical formulation. Like other
members of the lincosamide family, clindamycin is a broad spectrum antibiotic with activity against
anaerobic bacteria and protozoans. Clindamycin hydrochloride acts by binding to the 23S ribosomal
subunit, blocking protein synthesis. Clindamycin hydrochloride has been extensively studied with over
8,000 literature citations.
Lincomycin is a lincosamide antibiotic that comes from the actinomyces Streptomyces lincolnensis.A
related compound, clindamycin, is derived from lincomycin by using thionyl chloride to replace the 7-
hydroxy group with a chlorine atom with inversion of chirality.
Although similar in structure, antibacterial spectrum, and mechanism of action to macrolides, lincomycin
is also effective against other organisms including actinomycetes, mycoplasma, and some species of
Plasmodium.Intramuscular administration of a single dose of 600 mg of Lincomycin produces average
peak serum levels of 11.6 micrograms/ml at 60 minutes, and maintains therapeutic levels for 17 to 20
hours, for most susceptible gram-positive organisms. Urinary excretion after this dose ranges from 1.8
to 24.8 percent (mean: 17.3 percent).
A two-hour intravenous infusion of 600 mg of Lincomycin achieves average peak serum levels of 15.9
micrograms/ml and yields therapeutic levels for 14 hours for most susceptible gram-positive organisms.
Urinary excretion ranges from 4.9 to 30.3 percent (mean: 13.8 percent).
The biological half-life after IM or IV administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin
may be prolonged in patients with severe impairment of renal function, compared to patients with
normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer
than in patients with normal hepatic function. Hemodialysis and peritoneal dialysis are not effective in
removing lincomycin from the serum.
Tissue level studies indicate that bile is an important route of excretion. Significant levels have been
demonstrated in the majority of body tissues. Although lincomycin appears to diffuse in the
cerebrospinal fluid (CSF), levels of lincomycin in the CSF appear inadequate for the treatment of
meningitis.